A business in context

VOR research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-10-02 · 0001231919-26-001426

  2. 4 · Ownership change

    Report date 2026-08-24 · 0001231919-26-001102

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-343607

  4. 4 · Ownership change

    Report date 2026-07-16 · 0001231919-26-000776

  5. 4 · Ownership change

    Report date 2026-07-07 · 0001193125-26-299665

  6. 8-K · Current report

    Report date 2026-07-06 · 0001193125-26-297454 · Items 5.02,9.01

  7. 4 · Ownership change

    Report date 2026-06-11 · 0001231919-26-000633

  8. 4 · Ownership change

    Report date 2026-06-11 · 0001193125-26-270002

  9. 4 · Ownership change

    Report date 2026-06-11 · 0001193125-26-270000

  10. 4 · Ownership change

    Report date 2026-06-11 · 0001193125-26-269999

  11. 8-K · Current report

    Report date 2026-06-11 · 0001193125-26-269431 · Items 5.07,9.01

  12. 8-K · Current report

    Report date 2026-06-08 · 0001193125-26-261661 · Items 7.01,9.01

  13. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-220689

  14. DEF 14A · Proxy statement

    Report date 2026-04-23 · 0001193125-26-181883

  15. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-130451

  16. 8-K · Current report

    Report date 2026-03-26 · 0001193125-26-127609 · Items 1.01,3.02,7.01,9.01

  17. 8-K · Current report

    Report date 2026-01-12 · 0001193125-26-009961 · Items 2.02,7.01,9.01

  18. 8-K · Current report

    Report date 2025-12-31 · 0001193125-26-000905 · Items 5.02

  19. 8-K · Current report

    Report date 2025-12-15 · 0001193125-25-324768 · Items 1.01,3.02,5.02,7.01,9.01

  20. 8-K · Current report

    Report date 2025-12-05 · 0001193125-25-311957 · Items 5.02

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-280104

  22. 8-K · Current report

    Report date 2025-11-10 · 0001193125-25-275862 · Items 8.01,9.01

  23. 8-K · Current report

    Report date 2025-11-02 · 0001193125-25-261723 · Items 5.02,7.01,9.01

  24. 8-K · Current report

    Report date 2025-10-28 · 0001193125-25-253636 · Items 7.01,9.01

  25. 8-K · Current report

    Report date 2025-09-17 · 0001193125-25-205553 · Items 3.03,8.01,9.01

  26. 8-K · Current report

    Report date 2025-09-02 · 0001193125-25-193600 · Items 7.01,9.01

  27. 8-K · Current report

    Report date 2025-08-25 · 0001193125-25-189435 · Items 5.02

  28. 8-K · Current report

    Report date 2025-08-25 · 0001193125-25-189169 · Items 5.02,5.07,8.01,9.01

  29. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-107276

  30. DEF 14A · Proxy statement

    Report date 2025-08-25 · 0001140361-25-029749

  31. 8-K · Current report

    Report date 2025-07-16 · 0001193125-25-162644 · Items 5.02,7.01,9.01

  32. 8-K · Current report

    Report date 2025-07-09 · 0001193125-25-157638 · Items 5.02,7.01,9.01

  33. 8-K · Current report

    Report date 2025-06-25 · 0001193125-25-147339 · Items 1.01,1.02,3.02,5.02,7.01,9.01

  34. 8-K · Current report

    Report date 2025-05-22 · 0001193125-25-125833 · Items 5.03,5.07,9.01

  35. 8-K · Current report

    Report date 2025-05-19 · 0001193125-25-123141 · Items 5.02

  36. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-071349

  37. 8-K · Current report

    Report date 2025-05-05 · 0001193125-25-115554 · Items 2.05,5.02,8.01,9.01

  38. 8-K · Current report

    Report date 2025-04-22 · 0001193125-25-096692 · Items 3.01

  39. DEF 14A · Proxy statement

    Report date 2025-05-22 · 0001193125-25-075715

  40. 8-K · Current report

    Report date 2025-03-31 · 0001193125-25-072340 · Items 5.02

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 1 transaction rows1AExercise / conversion: 2 transaction rows2MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

6 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-24
2026-08-26
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.M · Exercise / conversion
Acquired
Common Stock1500.03.74
2026-08-24
2026-08-26
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
1500.00.0
2026-07-16
2026-07-21
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.X · Other (see filing)
Acquired
Common Stock2100000.00.0
2026-07-16
2026-07-21
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.S · Sale
Disposed
Common Stock213.019.75
2026-07-16
2026-07-21
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.X · Other (see filing)
Disposed
Pre-Funded Warrant (Right to Buy)
Derivative security
2100000.05.0
2026-07-07
2026-07-09
ZACCARDELLI DAVIDA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
42658.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001817229Vor Biopharma Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

    Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

    Explore the CPI history ↗